Changes in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia

July 21, 2026 updated by: Fang Luo, Beijing Tiantan Hospital

Changes in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia: a Prospective Cohort Study

To compare the dosage requirement of ciprofol under intravenous anesthesia between patients with insomnia and those with normal sleep pattern.

Study Overview

Status

Recruiting

Detailed Description

The investigators aim to investigate whether ciprofol dosage requirement is increased in patients with insomnia under intravenous anesthesia compared with normal sleep patterns.

Study Type

Observational

Enrollment (Estimated)

840

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100070
        • Recruiting
        • Beijing Tiantan Hospital
        • Principal Investigator:
          • Fang Luo, M.D.
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with insomnia and patients with normal sleep patterns

Description

Inclusion Criteria:

  • Patients with insomnia:

    1. Age of 18 - 64 years;
    2. ASA physical status of I - II;
    3. BMI of 15 - 30;
    4. Patients undergoing elective thoracoscopy, laparoscopy, hysteroscopy, open abdominal surgery, open thoracic surgery, open spinal surgery, craniotomy surgery, and digestive endoscopy under general anesthesia;
    5. Positive screening results according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for insomnia disorder;
    6. 8-item Sleep Condition Indicator (SCI; score 0-4; range 0-32, higher score means better sleep) scored 16 or less.
  • Patients with normal sleep:

    1. Age of 18 - 64 years;
    2. ASA physical status of I - II;
    3. BMI of 15 - 30;
    4. Patients undergoing elective thoracoscopy, laparoscopy, hysteroscopy, open abdominal surgery, open thoracic surgery, open spinal surgery, craniotomy surgery, and digestive endoscopy under general anesthesia;
    5. No history or evidence of insomnia.

Exclusion Criteria:

  1. Associated with any neurological disease;
  2. Daily alcohol consumption;
  3. Any contraindication to intravenous anesthetic drug, such as hypotension or shock;
  4. History of allergy to any drug used in the study;
  5. Pregnancy or breastfeeding;
  6. Patients with sleep apnea syndrome;
  7. acute upper respiratory infection;
  8. Patients with psychological diseases who report suicidal thoughts;
  9. Patients who need to work or take care of children/elderly people frequently at night.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Insomnia group
Patients with insomnia
No interventions, this study is to compare the dosage requirement of ciprofol under intravenous anesthesia between insomnia group and normal sleep group.
Normal sleep group
Patients with normal sleep
No interventions, this study is to compare the dosage requirement of ciprofol under intravenous anesthesia between insomnia group and normal sleep group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The total consumption of ciprofol
Time Frame: Up to 1 day
The total consumption of ciprofol under intravenous anesthesia. It includes the total amount of ciprofol required by the patient for the entire process of procedure.
Up to 1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The recovery time
Time Frame: Up to 1 day
The time from when the patient stops intravenous anesthetic drug application to when they can open their eyes and nod their heads.
Up to 1 day
Duration of patients' PACU stay
Time Frame: Up to 1 day
Patients' stay time in PACU
Up to 1 day
Patients' satisfaction
Time Frame: Up to 1 day
Patients' satisfaction with the procedure at this level of sedation (satisfactory/medium/unsatisfactory)
Up to 1 day
Patients' willingness
Time Frame: Up to 1 day
Patients' willingness to undergo the next procedure at the same level of sedation
Up to 1 day
The ease of operation at this level of sedation evaluated by the operation doctors
Time Frame: Up to 1 day
The ease of operation at this level of sedation (easy/medium/difficult) evaluated by the operation doctors
Up to 1 day
The satisfaction degree of anesthesia effect evaluated by the operation doctors
Time Frame: Up to 1 day
The satisfaction degree of anesthesia effect (satisfactory/medium/unsatisfactory) evaluated by the operation doctors
Up to 1 day
The dosage of ciprofol for anesthesia induction
Time Frame: 1 day
The dosage of ciprofol for anesthesia induction
1 day
The occurrence of the respiratory and cardiovascular adverse events
Time Frame: The day for patients undergoing procedure and 24 hours after the procedure
The occurrence of the respiratory and cardiovascular adverse events such as hypoxemia, hypotension, hypertension, arrhythmia
The day for patients undergoing procedure and 24 hours after the procedure
The occurrence of the other adverse events
Time Frame: The day for patients undergoing procedure and 24 hours after the procedure
The occurrence of the other adverse events such as dizziness, agitation, nausea, vomiting and psychiatric symptom
The day for patients undergoing procedure and 24 hours after the procedure
The incidence of intraoperative recall or awareness
Time Frame: The day for patients undergoing procedure and 24 hours after the procedure
The patient is conscious after anesthesia
The day for patients undergoing procedure and 24 hours after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 24, 2025

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

March 20, 2025

First Submitted That Met QC Criteria

March 20, 2025

First Posted (Actual)

March 26, 2025

Study Record Updates

Last Update Posted (Actual)

July 22, 2026

Last Update Submitted That Met QC Criteria

July 21, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Insomnia

Clinical Trials on No interventions, it is a observational study

Subscribe